Literature DB >> 17542278

[Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects].

Javier Lizardi-Cervera1, Dra Ivonne Becerra Laparra, Norberto C Chávez-Tapia, Martha E Ramos Ostos, Misael Uribe Esquivel.   

Abstract

UNLABELLED: Non Alcoholic Fatty Liver Disease (NAFLD) is a frequent entity to progress to liver fibrosis and cirrhosis, and it is associated with several metabolic disturbances. The insulin resistance is often considered the link between metabolic disturbances and NAFLD. The aim of this study was to determine the prevalence of NAFLD in healthy population and the prevalence of metabolic syndrome in this patients. The associated factors to develop liver cirrhosis were identified.
METHODS: 2,503 records were reviewed and the presence of steatosis was determined by ultrasonography. A clinical and biochemical examination was carried out and the metabolic criteria were defined according to the ATP III.
RESULTS: 427 (17.05%) patients with NAFLD were detected. 359 (14.3%) with NAFLD were included, the mean age was 46.26 +/- 9.85 years. Overweight was present in 46.79% and obesity in 36.49% of patients. The association between DM, HAS, high levels of cholesterol and triglicerides was found in 3.6, 13.6, 63 and 43%, respectively. Steatohepatitis was found in in 34% of patients high levels of AST. AST/ALT ratio > 1 was detected in 76 patients (21.16%). According to the ATP III criteria, the prevalence of metabolic syndrome in patients with NAFLD was 22.8%.
CONCLUSIONS: The frequency of NAFLD and metabolic syndrome in this study was 14.3% and 22.8%, respectively. Overweight, obesity and dyslipidemia were the main associated factors to NAFLD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17542278

Source DB:  PubMed          Journal:  Rev Gastroenterol Mex        ISSN: 0375-0906


  9 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

Review 2.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

3.  Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases.

Authors:  Hüseyin Saadettin Uslusoy; Selim-Giray Nak; Macit Gülten; Zeynep Biyikli
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

4.  Non-alcoholic steatohepatitis with normal aminotransferase values.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten; Zeynep Biyikli
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

Review 5.  Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations.

Authors:  Zaki A Sherif; Armana Saeed; Shima Ghavimi; Seyed-Mehdi Nouraie; Adeyinka O Laiyemo; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2016-04-01       Impact factor: 3.199

6.  Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Authors:  Rebeca Escutia-Gutiérrez; J Samael Rodríguez-Sanabria; C Alejandra Monraz-Méndez; Jesús García-Bañuelos; Arturo Santos-García; Ana Sandoval-Rodríguez; Juan Armendáriz-Borunda
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

7.  Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology.

Authors:  Chimaobi M Anugwom; Manon Allaire; Sheikh Mohammad Fazle Akbar; Amir Sultan; Steven Bollipo; Angelo Z Mattos; Jose D Debes
Journal:  Hepatoma Res       Date:  2021-03-26

Review 8.  Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.

Authors:  Huapeng Lin; Xinrong Zhang; Guanlin Li; Grace Lai-Hung Wong; Vincent Wai-Sun Wong
Journal:  J Clin Transl Hepatol       Date:  2021-08-30

9.  Effect of LncPVT1/miR-20a-5p on Lipid Metabolism and Insulin Resistance in NAFLD.

Authors:  Han Zhang; Qinghui Niu; Kun Liang; Xuesen Li; Jing Jiang; Cheng Bian
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-23       Impact factor: 3.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.